Patent intelligence · AU
AU 2021290177
A recombinant Modified Vaccinia Virus Ankara (MVA) vaccine against coronavirus disease
A recombinant Modified Vaccinia Virus Ankara (MVA) vaccine against coronavirus disease
Patent details — AU 2021290177
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Jan 19, 2023
- Expiration
- Jan 14, 2043
- Applicant
- BAVARIAN NORDIC AS [DK]
- CPC classes
- A61K 39/ 12 A I, A61K/3912, A61K/39215, A61P 31/ 14 A I
Quick answer
AU 2021290177 (A recombinant Modified Vaccinia Virus Ankara (MVA) vaccine against coronavirus disease) is held by BAVARIAN NORDIC AS [DK]. Status: granted. Granted Jan 19, 2023. Expires Jan 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAVARIAN NORDIC AS [DK]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 12 A I, A61K/3912, A61K/39215, A61P 31/ 14 A I, A61P/3114
More from BAVARIAN NORDIC AS [DK]
Related pharmaceutical patents in our USPTO index.
-
WO 2026104630
MÉTHODE DE SÉLECTION DOMINANTE PERMANENTE POUR LA GÉNÉRATION DU VIRUS ANKARA DE LA VACCINE MODIFIÉ RECOMBINANT (MVA)
granted -
WO 2026062034
NANOPARTICULES DE PROTÉINE AFFICHANT DES ANTIGÈNES DE MALADIE DE LYME
granted -
WO 2025238218
VECTEURS VIRAUX CODANT POUR DES NANOPARTICULES DE PROTÉINE D'AFFICHAGE D'ANTIGÈNE
granted -
WO 2025238221
VECTEURS VIRAUX CODANT POUR DES NANOPARTICULES DE PROTÉINE À PRÉSENTATION D'ANTIGÈNES MULTIPLES
granted -
WO 2025238220
ACIDES NUCLÉIQUES POUR LA VACCINATION CODANT POUR DES NANOPARTICULES DE PROTÉINE DE PRÉSENTATION DES ANTIGÈNES
granted -
WO 2025238219
VIRUS MODIFIÉ DE LA VACCINE ANKARA (MVA) CODANT POUR DES NANOPARTICULES PROTÉIQUES PRÉSENTANT DES ANTIGÈNES
granted -
US 2025002606
Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA
granted -
WO 2024188801
UTILISATION DE LIGNÉES CELLULAIRES DE CAILLE POUR PRODUCTION DE POXVIRUS
granted
Frequently asked questions
What is US patent 2021290177?
AU 2021290177 (A recombinant Modified Vaccinia Virus Ankara (MVA) vaccine against coronavirus disease) is held by BAVARIAN NORDIC AS [DK]. Status: granted. Granted Jan 19, 2023. Expires Jan 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2021290177?
BAVARIAN NORDIC AS [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AU 2021290177 expire?
Our index shows an expiration date of Jan 14, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.